Short answer
ARDELYX, INC. (ARDX) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $94M (up 27.5% year over year) with net income of −$38M.
Q1 2026 key financials · XBRL
- Revenue
- $94M
- +27.5% YoY
- Net income
- −$38M
- +8.6% YoY
- Operating margin
- -34.7%
- EPS (diluted)
- −$0.15
- +11.8% YoY
Source: XBRL data from the ARDELYX, INC. (ARDX) Q1 2026 10-Q on SEC EDGAR. USD.
ARDELYX, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $94.5M, up 27% YoY from $74.1M
- IBSRELA sales $70.1M, up 58% YoY; XPHOZAH $23.3M, down $0.1M
- GTN adjustment rate 36.3% vs 29.9% YoY
- Operating cash use $32.2M vs $38.5M; liquid funds $238.1M vs $264.7M
- ACCEL enrollment expected complete by year-end 2026; topline data expected second half 2027
Risk Factors
- XPHOZAH Medicare Part D coverage eliminated January 1, 2025 after ESRD PPS inclusion, materially reducing 2025 revenue
- Accumulated deficit $984.5 million as of March 31, 2026, with continued losses limiting cash-flow sustainability
- Current administration actions could pressure IBSRELA and XPHOZAH pricing, reducing future product revenue
- Third-party manufacturers and single-source suppliers face cGMP, raw-material, and capacity risks affecting product availability
- Additional financing may be required for commercialization, clinical trials, pipeline investments, and SLR loan principal and interest payments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARDELYX, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.